Market Intelligence, Clinical Progress, and High-Purity Reagents for Regenerative Medicine, Fibrosis & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WNT7A/B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| WNT7A Full Length Protein | HEK293 Expressed (Native Palmitoylation), Sequence Verified, High Purity (>90% by SDS-PAGE, <1EU/µg endotoxin) | View WNT7A Products |
| WNT7B Mature Domain Protein | HEK293 Expressed, Lipid-modified, Theoretical MW ~40kDa (Glycosylated), High Purity (>90%) | View WNT7B Products |
| Gene Delivery (WNT7A) | WNT7A Promise-ORF / Lentivirus – Full-length ORF for stable cell lines | View WNT7A Products |
| Benchmark Antibody | Anti-WNT7A/B Biosimilar – Recombinant positive control for assay validation | View WNT7B Products |
| Validator siRNA | WNT7A / WNT7B siRNA Set – For knockdown verification in pathway analysis | View WNT7A Products |
| Receptor ECD (FZD5) | Frizzled-5 CRD-Fc Fusion Protein – WNT7A Primary Receptor, Human/Mouse Orthologs, >95% Purity | View FZD5 Products |
| Co-receptor (LRP6) | LRP6 E1–E2 Domain Protein – Essential for Canonical Signaling, Binding Affinity Control | View LRP6 Products |
| Pathway Control (WNT5A) | WNT5A Protein – Non-canonical Wnt Control for Specificity Testing | View WNT5A Products |
| Reporter System | TCF/LEF-Luc Lentivirus Particles – Stable β-catenin Reporter for Wnt Activity Quantification | View CTNNB1 Products |
| Related Target: FZD4 | Frizzled-4 – Primary Wnt receptor critical for BBB angiogenesis | View FZD4 Products |
| Related Target: GPR124 | GPR124 (ADGRA2) – Co-receptor specific to WNT7A/B signaling at the BBB | View GPR124 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein Folding & Lipid Modification Preservation | Native HEK293 Expression System preserving palmitoylation sites (Cys104 equivalent); Essential for Frizzled binding activity; Sequence Verified |
| Receptor Selectivity Profiling | FZD5 vs FZD7 ECD-Fc Panel Available (Sequence Verified) for canonical vs non-canonical discrimination; Homolog panel by mass spec |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included; Matched WNT5A (Non-canonical) and WNT3A (Canonical) proteins for cross-family screening |
| False Positive Reduction in Cell Assays | Validated siRNA included for specificity checks and background reduction |
| Soluble Ligand Stability | Detergent-formulated or Carrier protein options (BSA/FCS) to prevent hydrophobic aggregation; Aggregation <5% by DLS |
| Cell Line Construction | WNT7A/B ORF Lentivirus for stable overexpression in fibroblast/epithelial lines; Puromycin selection marker included |
Live WNT7A/B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active WNT7A Clinical Trials
- ➤ View Active WNT7B Clinical Trials
- ➤ Latest Resistance Research (WNT7A+WNT7B drug resistance)
- ➤ Latest Fibrosis & Wnt Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The WNT7 ligand family is emerging as a critical node in tissue regeneration, fibrotic disease, and oncology. Unlike the broadly expressed WNT3A, WNT7A and WNT7B exhibit tissue-specific roles: WNT7A drives alveolar epithelial regeneration (relevant for Idiopathic Pulmonary Fibrosis, IPF) and muscle repair, while WNT7B regulates angiogenesis and blood-brain barrier (BBB) integrity via the GPR124/RECK co-receptor axis. First-generation broadly-acting Wnt pathway inhibitors (Porcupine inhibitors) faced significant toxicity; the next wave of R&D targets highly specific ligand-receptor interactions (e.g., WNT7A-GPR124-RECK for CNS, WNT7A-FZD5 for lung) to achieve tissue-selective modulation. Recombinant WNT7A agonists (e.g., Surrozen SRZN-135) are entering Phase I for IPF, while FZD decoy receptors and monoclonal antibodies are being developed for solid tumors. Gene therapy approaches for CNS and kidney fibrosis also leverage WNT7A/B expression validation tools.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Ligands / Agonists | Surrozen (SRZN-135), Early Biotech, Academic Spin-offs | IPF, Alveolar Repair, BBB Repair, Stroke, Myopathies | High-purity functional analogs (HEK293 derived); FZD5 binding affinity |
| Monoclonal Antibodies (Antagonists) | OncoMed, Oncology Innovators | Solid Tumors (Lung, Pancreatic, Breast – WNT7B high expression) | Epitope mapping (full-length vs truncated WNT7); cross-reactive Abs |
| FZD Decoy Receptor | Deciphera, IPA | Solid Tumors | Competition assay (WNT7A/B vs FZD8-Fc chimera) |
| Gene Therapy (AAV) | Neuro-focused Pharma, Various Academic | CNS Disorders, Kidney Fibrosis | Expression validation (ORF Lentivirus for cell lines; Validated siRNA) |